• Publications
  • Influence
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
This article is an update of the International Consensus Report published in 2010, and provides consensus recommendations on the diagnosis and management of ITP in adults, during pregnancy, and in children, as well as quality-of-life considerations.
Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia
Light is shed on Fc-independent cytopenias, designating desialylation as a potential diagnostic biomarker and therapeutic target in the treatment of refractory ITP.
Th22 Cells as Well as Th17 Cells Expand Differentially in Patients with Early-Stage and Late-Stage Myelodysplastic Syndrome
L-MDS cohort had increased frequencies of peripheral Th 22 cells and higher mRNA expression levels of IL-6 and TNF-α, indicating that Th22 cells along with Th17 cells or not are involved in the dynamic immune responses of MDS.
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
This large real-world study demonstrates that chidamide has a favorable efficacy and an acceptable safety profile for refractory and relapsed PTCL patients but requires further investigation.
Elevated Interleukin-21 Correlated to Th17 and Th1 Cells in Patients with Immune Thrombocytopenia
Together, the results indicated a possible role of IL-21 in ITP patients correlated to Th17 and Th1 cells, and blockade ofIL-21 may be a reasonable therapeutic strategy for ITP especially those with active disease.
Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti‐platelet GPIIbIIIa versus GPIbα antibodies
The preliminary findings of this study suggest that in future prospective clinical trials including corticosteroids, the anti‐GPIbα, and ‐GPIIbIIIa status should be assessed in order to test its potential relevance in deciding future treatments.
A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.
It is demonstrated that the combination of RTX and rhTPO significantly increased the CR rate and shortened TTR compared with RTX monotherapy in the treatment of corticosteroid-resistant or relapsed ITP but failed to show a beneficial effect on the long-lasting response.